This study demonstrates significant increases in flux through aerobic glycolysis, oxidative phosphorylation, and glutaminolysis with development of therapeutic resistance to androgen deprivation therapy using patient-derived cell lines and a transgenic murine model. Based on these metabolic differences between androgen-sensitive and insensitive prostate cancer, a combination of hyperpolarized [1-13C]pyruvate, [2-13C]pyruvate and [5-13C]glutamine can be used to noninvasively predict therapeutic resistance in future patient studies using HP 13C MRI.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords